SIOPEN Publications
Image-defined risk factors in unresectable neuroblastoma: SIOPEN study on incidence, chemotherapy-induced variation, and impact on surgical outcomes
Avanzini S, Pio L, Erminio G, Granata C, Holmes K, Gambart M, Buffa P, Castel V, Valteau Couanet D, Garaventa A, Pistorio A, Cecchetto G, Martucciello G, Mattioli G, Sarnacki S
Pediatr Blood Cancer. 2017 Nov;64(11). doi: 10.1002/pbc.26605. Epub 2017 Apr 25. PMID: 28440012.
Accelerating drug development for neuroblastoma - New Drug Development Strategy: an ITCC, ENCCA and Adolescents and SIOPEN project
Moreno L, Caron H, Geoerger B, Eggert A, Schleiermacher G, Brock P, Valteau-Couanet D, Chesler L, Schulte JH, De Preter K, Molenaar J, Schramm A, Eilers M, Van Maerken T, Johnsen JI, Garrett M, George SL, Tweddle DA, Kogner P, Berthold F, Koster J, Barone G, Tucker ER, Marshall L, Herold R, Sterba J, Norga K, Vassal G, Pearson AD.
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D.
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as HD chemotherapy for HR neuroblastoma (HR-NBL1 ph3 trial /SIOPEN)
Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, Yaniv I, Papadakis V, Laureys G, Malis J, Balwierz W, Ruud E, Kogner P, Schroeder H, de Lacerda AF, Beck-Popovic M, Bician P, Garami M, Trahair T, Canete A, Ambros PF, Holmes K, Gaze M, Schreier G, Garaventa A, Vassal G, Michon J, Valteau-Couanet D.
Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma …
…on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group .
Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F.
Cancer. 2017 Apr 1;123(7):1095-1105. doi: 10.1002/cncr.30380. Epub 2016 Dec 16. PMID: 27984660.
(123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel
Lewington V, Lambert B, Poetschger U, Sever ZB, Giammarile F, McEwan AJB, Castellani R, Lynch T, Shulkin B, Drobics M, Staudenherz A, Ladenstein R.
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials
Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD
Pediatr Blood Cancer. 2017 Jan;64(1):25-31.doi: 10.1002/pbc.26192.Epub 2016 Aug 24